Other studies demonstrated an opposite picture, with decreased Gal-3 expression in breast, ovarian cancer prostate tumors, advanced uterine adenocarcinoma, basal cell carcinoma of the skin, epithelial skin cancer and malignant salivary gland neoplasms, compared to the corresponding normal tissue. This evidence concerns the gene LGALS3 and ovarian cancer.